The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors.
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors.
复制标题
DOI：
10.1016/j.ccell.2023.09.016
复制
发表时间：
2023-10
期刊：
影响因子：
50.3
通讯作者：
Juyeun Lee;J. Lathia
中科院分区：
文献类型：
--
作者：
Juyeun Lee;J. Lathia
弥漫性中线神经胶质瘤（DMG）由于其位于脑干内且具有侵袭性，因此给治疗带来挑战。虽然经典的免疫检查点抑制剂在临床试验中表现出有限的成功，但Ausejo-Mauleon et al.证明TIM-3是一种有效的DMG策略，靶向免疫细胞和肿瘤细胞，具有双重治疗益处。
Diffuse midline gliomas (DMGs) pose treatment challenges due to their location within the brainstem and invasive nature. Although classical immune checkpoint inhibitors have demonstrated limited success in clinical trials, Ausejo-Mauleon et al. demonstrate TIM-3 is an effective DMG strategy, targeting both immune and tumor cells for dual therapeutic benefit.